Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes

Ida, Tomoko; Asai, Tomohiro; Maeda, Noriyuki; Oku, Naoto

doi:10.1016/j.ijpharm.2008.04.046

Cited by 31 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[89][90][91][92] oku and colleagues determined that the alanineplorine-arginine-plorine-glycine (APRPG) motif peptide specifically binds to tumor angiogenic vessels and demonstrated the utility of APRPG-modified PEG liposomes. 93,94) 3.2. De-PEGylation After glycoproteins are recognized by lipoplexes, endocytosis or endocytosis-like pathways occur for their internalization.…”

Section: -28)mentioning

confidence: 99%

The Polyethyleneglycol Dilemma: Advantage and Disadvantage of PEGylation of Liposomes for Systemic Genes and Nucleic Acids Delivery to Tumors

Hatakeyama

Akita

Harashima

2013

Biological & Pharmaceutical Bulletin

421

276

View full text Add to dashboard Cite

Gene and nucleic acid therapy is expected to play a major role in the next generation of agents for cancer treatment. We have recently developed a multifunctional envelope-type nano device (MEND) for use as a novel nonviral gene delivery system. The modification of polyethyleneglycol (PEG), i.e., PEGylation, is a useful method for achieving a longer circulation time for the delivery of MEND to a tumor via the enhanced permeability and retention (EPR) effect. However, PEGylation strongly inhibits cellular uptake and endosomal escape, which results in significant loss of activity of the delivery system. For successful nucleic acid delivery for cancer treatment, the crucial problem associated with the use of PEG, i.e., the "PEG dilemma" must be resolved. In this review, we describe the development and applications of MEND and discuss various strategies for overcoming the PEG dilemma based on the manipulation of both pharmacokinetics and intracellular trafficking of cellular uptake and endosomal release. To increase cellular uptake, target ligands including proteins, peptides, antibodies and aptamers that recognize molecules specifically expressed on tumors are first introduced. Second, cleavable PEG systems are described. The cleavage of PEG from carriers was achieved in response to the intracellular environment as well as the tumor microenvironment, which improvs cellular uptake and endosomal escape. Then, endosomal fusogenic peptides are discussed. Finally, pH-sensitive liposomes using pH-sensitive lipids are described.

show abstract

Section: -28)mentioning

confidence: 99%

The Polyethyleneglycol Dilemma: Advantage and Disadvantage of PEGylation of Liposomes for Systemic Genes and Nucleic Acids Delivery to Tumors

Hatakeyama

Akita

Harashima

2013

Biological & Pharmaceutical Bulletin

421

276

View full text Add to dashboard Cite

show abstract

“…SU5402 interacts with the catalytic domain of the FGFR1 (Mohammadi et al 1997) and has been used in numerous studies to specifically block FGF signalling and FGF2-induced angiogenesis (Numata et al 2006, Nicoli et al 2009). SU1498 inhibits tyrosine phosphorylation of VEGFR2, resulting in the suppression of endothelial cell proliferation in response to VEGF, and an inhibition of angiogenesis (Strawn et al 1996, Katanasaka et al 2008. Tyrphostin AG1295 has been reported to abolish autophosphorylation of the PDGF receptors and to block PDGF-stimulated DNA synthesis in endothelial cells (Kovalenko et al 1994).…”

Section: Effect Of Angiogenic Inhibitors On Endothelial Cell Network mentioning

confidence: 99%

FGF2 is crucial for the development of bovine luteal endothelial networks in vitro

Woad¹,

Hammond²,

Mann³

et al. 2009

Reproduction

View full text Add to dashboard Cite

The development of the corpus luteum requires angiogenesis, and involves the complex interplay between factors such as vascular endothelial growth factor A (VEGFA), fibroblast growth factor 2 (FGF2) and platelet-derived growth factor (PDGF). However, the relative role of these factors remains to be elucidated. This study used a new physiologically relevant mixed luteal cell culture system to test the hypotheses that: a) FGF2 and VEGFA are critical for bovine luteal angiogenesis; and b) local luteal PDGF signalling stimulates the formation of endothelial networks. Cells were treated with receptor tyrosine kinase inhibitors against VEGFA (SU1498), FGF2 (SU5402) or PDGF (AG1295) activity. After 9 days in culture, endothelial cells were immunostained for von Willebrand factor (VWF) and quantified by image analysis. Highly organised intricate endothelial networks were formed in the presence of exogenous VEGFA and FGF2. The inhibition of FGF2 activity reduced the total area of VWF staining versus controls (O95%; P!0.001). Inhibition of VEGF and PDGF activity reduced the endothelial network formation by more than 60 and 75% respectively (P!0.05). Progesterone production increased in all treatments from day 1 to 7 (P!0.001), and was unaffected by FGF2 or PDGF receptor kinase inhibition (PO0.05), but was reduced by the VEGF receptor inhibitor on days 5 and 7 (P!0.001). In conclusion, this study confirmed that VEGF signalling regulates both bovine luteal angiogenesis and progesterone production. However, FGF2 was crucial for luteal endothelial network formation. Also, for the first time, this study showed that local luteal PDGF activity regulates bovine luteal endothelial network formation in vitro.

show abstract

“…To overcome the problems, it is important to use the tools of drug delivery systems. 44,45) Indeed, several drug delivery systems such as micelles, 46) liposomes, 47) nanoparticles, 48) and nanoemulsions 49) have been designed to improve the bioavailability of curcumin and to be used for pharmacological therapy. 50) We have developed Theracurcumin ® (Theravalues corporation, chiyoda-ku, Tokyo, Japan), a highly absorbable curcumin formulation that is easily and stably dispersible in water, by nanoparticulation and surface-processing techniques.…”

Section: Clinical Application Of Curcumin For Heart Failurementioning

confidence: 99%

Application of Curcumin to Heart Failure Therapy by Targeting Transcriptional Pathway in Cardiomyocytes

Sunagawa

Hasegawa

Morimoto

2013

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Heart failure is one of the leading causes of death throughout the world. During the development and deterioration processes of heart failure, cardiomyocytes undergo maladaptive hypertrophy by altering hypertrophy-related gene expression. The zinc finger protein GATA4 is one of the transcription factors involved in the regulation of cardiomyocyte hypertrophy. In response to hypertrophic stimuli such as the synaptic nervous and rennin-angiotensin systems, GATA4 forms a large complex with various functional proteins including an intrinsic histone acetyltransferase, p300, and the disruption of this complex results in the inhibition of hypertrophic responses in cardiomyocytes. While such a transcriptional signal pathway is recognized as a critical event during cardiomyocyte hypertrophy, pharmacological heart failure therapy that targets this pathway has not been established. In order to develop novel heart failure therapy targeting the pathway in cardiomyocytes, we have studied the potential of curcumin, a p300 histone acetyltransferase inhibitor, as an agent for novel heart failure therapy. In this review, we describe a recent study on the cardiac transcriptional signal pathway, especially p300/GATA4 pathway, and a novel heart failure therapy using curcumin.

show abstract

Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes

Cited by 31 publications

References 22 publications

The Polyethyleneglycol Dilemma: Advantage and Disadvantage of PEGylation of Liposomes for Systemic Genes and Nucleic Acids Delivery to Tumors

The Polyethyleneglycol Dilemma: Advantage and Disadvantage of PEGylation of Liposomes for Systemic Genes and Nucleic Acids Delivery to Tumors

FGF2 is crucial for the development of bovine luteal endothelial networks in vitro

Application of Curcumin to Heart Failure Therapy by Targeting Transcriptional Pathway in Cardiomyocytes

Contact Info

Product

Resources

About